Author Archive: BIOtechNOW Editor

FDA Safety and Innovation Act: A Step Forward for Patients With Rare Diseases

Peter L. Saltonstall

By Peter L. Saltonstall, President and CEO, National Organization for Rare Disorders (NORD) The Food and Drug Administration Safety and Innovation Act (FDASIA) includes the most groundbreaking measures for rare disease patients and their families since the Orphan Drug Act of 1983.  And, just as the rare disease patient community—with NORD as its unifying voice—played a major role in the Orphan Drug Act, NORD and rare disease patients have taken a leadership role in developing Read More >

Health  |  13 Comments  |  Email This Post
Tags: , , , , , , , , ,

The Cause Endures

t-kennedy-cause

By David Welch, M2 MultiMedia Communications In producing this short form mini-documentary, I learned that neither the conservatives who tried always to make Senator Ted Kennedy the poster child of all that was liberal nor the die-hard liberals who adored his every move had him quite right. This is especially true when examining his aggressive pursuit of his lifelong cause to improve the health of patients. It was a cause that propelled him into an Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,

Analysis and Impact of PDUFA V

hamburg

As the House of Representatives voted unanimously to approve legislation to approve the Prescription Drug User Fee Act (PDUFA) V, industry leaders gathered at the 2012 BIO International Convention for a lively discussion on the changes the new legislation, focused on modernizing Food and Drug Administration regulations, will bring to the biotechnology industry. The super session panel discussion was moderated by Steve Usdin, Washington Editor of BioCentury and Co-Host of BioCentury This Week, and included Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

BIO 2012 Super Session Recap: Burrill State-of-the-Industry Report

Business Forum

“How are we doing? It’s tough.” That’s what G. Steven Burrill, CEO of Burrill & Company, said at the outset of his talk to a fully packed room at the 2012 BIO International Convention Super Session featuring an overview of the 26th annual Burrill State-of-the-Industry Report. The report’s main finding was that the biotech industry is changing at a rapid pace, and is confronting a significant and newfound adversity in austerity that is caused by Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Cancer Research Pioneer Dr. Margaret Foti named 2012 Biotech Humanitarian Honoree

Dr. Margaret Foti

Today, BIO named Dr. Margaret Foti, , Ph.D., M.D. (h.c.), CEO of the American Association of Cancer Research, as the 2012 Biotech Humanitarian Honoree.  Dr. Foti was honored for her tireless efforts to improve cancer research, her work as a cancer advocate and her ground-breaking work in the area of team science. Dr. Foti is also known for her work leading AACR’s scientific partnership with Stand Up To Cancer — a charitable initiative that supports Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , ,